In addition, activation of the NF-kB pathway in pancreatic cancer stem cells is dependent on methylation of the downstream regulatory gene SOX9, and DNA methyltransferase inhibitors may represent a novel therapeutic option for pancreatic cancer treatment [173]. The gene discussed is SOX9; the disease is pancreatic neoplasm.